Mylan Launches First Generic Version of Teveten Tablets

Mylan Inc.

today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Eprosartan Mesylate Tablets, 400 mg and 600 mg. This product is the generic version of Abbott Laboratories' Teveten ^ Tablets, which are used to treat hypertension.